BioTuesdays

Tag - William Blair

Solid Biosciences Logo
Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

March 28, 2024
MDXHealth-logo
Markets

WB starts MDxHealth at outperform

William Blair launched coverage of MDxHealth S.A. (NASDAQ:MDXH) with an “outperform” rating. The stock closed at $2.86 on March 23. Analyst Andrew Brackmann writes that the rating is based on his belief that the company...

March 24, 2023
Mesoblast-Logo
Markets

WB starts Mesoblast at OP; fair value estimate $8

William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...

March 9, 2023
Janux Logo
Markets

WB starts Janux Therapeutics at OP

William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...

November 14, 2022
Akouos
Markets

WB starts Akouos at OP; fair value estimate $12

William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...

September 29, 2022
Point Biopharma Logo
Markets

WB starts POINT Biopharma at outperform

William Blair initiated coverage of POINT Biopharma Global (NASDAQ:PNT) with an “outperform” rating based on a view that the Street is “underestimating the clinical and commercial potential of the company’s...

July 6, 2022